See the DrugPatentWatch profile for cosentyx

Cosentyx, also known as secukinumab, is a medication used to treat various inflammatory diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a monoclonal antibody that targets interleukin-17A (IL-17A), a protein involved in inflammation [1].

Regarding the influence of Cosentyx on vaccine protection levels, there is limited information available. However, a study published in the Journal of Allergy and Clinical Immunology reported that treatment with secukinumab did not affect the immune response to pneumococcal and tetanus toxoid vaccines in patients with psoriasis [2]. This suggests that Cosentyx may not have a significant impact on vaccine protection levels.

It is important to note that patients on immunosuppressive therapies, including biologics like Cosentyx, may have a reduced response to vaccines [3]. Therefore, it is recommended that patients discuss their vaccination status and plans with their healthcare provider before starting or while on Cosentyx [3].

In summary, while there is limited information on how Cosentyx influences vaccine protection levels, a study suggests that it does not affect the immune response to certain vaccines in patients with psoriasis. However, patients on immunosuppressive therapies, including Cosentyx, may have a reduced response to vaccines.

Sources:

1. Cosentyx (secukinumab) [Internet]. DrugPatentWatch.com. 2021 [cited 2023 Mar 21]. Available from: <https://www.drugpatentwatch.com/drugs/cosentyx>.
2. Reich K, Blauvelt A, de Wit P, et al. Secukinumab does not impair immune responses to pneumococcal and tetanus toxoid vaccination in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2017;140(2):562-570.e4. doi:10.1016/j.jaci.2017.05.011
3. Vaccination in special circumstances: pregnancy, immunosuppression, and other special situations [Internet]. Centers for Disease Control and Prevention. 2022 [cited 2023 Mar 21]. Available from: <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/special-situations/index.html>